Antiviral drug
Chronic hepatitis C: IFNα2Β 3ΜU 3 times weekly for 6–12 months has produced remission in 50–70% patients. Viral RNA becomes undetectable and liver function tests return to normal. Histology improves if response is sustained. However, relapses occur in majority of patients. PegIFNs 180 μg/week are more effective and induce longer lasting remissions. Combination therapy with IFN/pegIFN + ribavirin is particularly indicated in patients who do not respond to IFN alone.